Biogen (BIIB) PT Lowered to $200 at Barclays

April 25, 2024 3:31 AM

Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $200.00 (from $215.00) while maintaining a Equalweight rating.

No results found